Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy

Future Virology

Volumn 7, Issue 8, 2012, Pages 819-832

  Shults, Keith ^a,b   Flye Blakemore, Leanne ^a   Patterson, Bruce K ^b,c,d   Elbeik, Tarek ^e  

^a Advanced Cytometric Applications   (United States)

^b IncellDx Inc ^*  (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Elbeik Associates LLC   (United States)

Author keywords

activated memory T cell; antiretroviral; cellular reservoirs; HIV 1; macrophage; memory T cell; monocyte; naive T cell; total CD4+; transcriptionally active

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; MESSENGER RNA;

CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN SITU HYBRIDIZATION; LIGHT SCATTERING; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; REVIEW; SIMULTANEOUS ULTRASENSITIVE SUBPOPULATION STAINING; T LYMPHOCYTE; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865513216     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.69     Document Type: Review

References (70)

1. Chattopadhyay PK, Roederer M. Good cell, bad cell: Flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A 77, 614-622 (2010).
2. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6, 388-400 (2008).
3. Chun TW, Murray D, Justement JS et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 204(1), 135-138 (2011).
4. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. Plos Pathog. 7(2), E1001303 (2011).
5. d'Ettorre G, Zaffiri L, Ceccarelli G, Mastroianni CM, Vullo V. The role of HIV-DNA testing in clinical practice. New Microbiol. 33(1), 1-11 (2010).
6. Gil C, Garcia MT, Garcia F et al. Evaluation of the Roche COBAS® TaqMan® HIV-1 test for quantifying HIV-1 RNA in infected cells and lymphoid tissue. J. Virol. Methods 174, 69-76 (2011).
7. Soares RS, Tendeiro R, Foxall RB et al. Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J. Virol. 85, 2429-2438 (2011).
8. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. Plos One 4, E8490 (2009).
9. Kupfer B, Matz B, Däumer MP et al. Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml. J. Med. Virol. 79, 1440-1445 (2007). (Pubitemid 47328731)
10. Kaiser P, Joos B, Niederöst B, Weber R, Günthard HF, Fischer M. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J. Virol. 81, 9693-9706 (2007). (Pubitemid 350067674)
11. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: The intersection between HIV infection and atherosclerosis. J. Leukoc. Biol. 87, 589-598 (2010).
12. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60, 471-484 (2009).
13. Fernandez S, Lim A, French M. Immune activation and the pathogenesis of HIV disease: Implications for therapy. J. HIV Ther. 14, 52-56 (2009).
14. Smith D. HIV as an inflammatory disease. J. HIV Ther. 14, 50-51 (2009).
15. Rong L, Perelson AS. Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. Plos Comput. Biol. 5, 1-18 (2009).
16. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 22, 439-446 (2008). (Pubitemid 351317285)
17. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 15, 483-493 (2007). (Pubitemid 47294919)
18. Elbeik T, Hoo BS, Campodonico ME et al. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/ml that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J. Hum. Virol. 4, 317-328 (2001). (Pubitemid 34693879)
19. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
20. Patterson BK. Simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI) in HIV-1 disease monitoring. Methods Mol. Biol. 659, 337-346 (2010).
21. Patterson BK, McCallister S, Schutz M et al. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 15, 1635-1641 (2001). (Pubitemid 32923062)
22. Patterson BK, Carlo DJ, Kaplan MH, Marecki M, Pawha S. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS 13(13), 1607-1611 (1999). (Pubitemid 30015706)
23. Patterson BK, Mosiman VL, Cantarero L, Furtado M, Bhattacharya M, Goolsby C. Detection of HIV-RNA-positive monocytes in peripheral blood of HIV-positive patients by simultaneous flow cytometric analysis of intracellular HIV RNA and cellular immunophenotype. Cytometry 31, 265-274 (1998). (Pubitemid 28162978)
24. Coquillard G, Patterson BK. Determination of hepatitis C virus-infected, monocyte lineage reservoirs in individuals with or without HIV coinfection. J. Infect. Dis. 200, 947-954 (2009).
25. Patterson BK, Behbahani H, Kabat WJ et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J. Clin. Invest. 107, 287-294 (2001). (Pubitemid 32162154)
26. Behbahani H, Popek E, Garcia P et al. Up-regulation of CCR5 expression in the placenta is associated with human immunodeficiency virus-1 vertical transmission. Am. J. Pathol. 157, 1811-1818 (2000).
27. Craigo JK, Patterson BK, Paranjpe S, Kulka K, Ding M. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res. Hum. Retroviruses 20(11), 1196-1209 (2004). (Pubitemid 39557870)
28. Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6, 475-479 (2000). (Pubitemid 30208169)
29. Pett SL, McCarthy MC, Cooper DA et al. A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients. Antivir. Ther. 14, 111-115 (2009).
30. Patterson BK, Czerniewski MA, Pottage J, Agnoli M, Kessler H, Landay A. Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Lancet 353(9148), 211-212 (1999). (Pubitemid 29088043)
31. Folks TM, Clouse KA, Justement J et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl Acad. Sci. USA 86(7), 2365-2368 (1998).
32. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine induced expression of HIV-1 in a chronically-infected promonocyte cell line. Science 238, 800-802 (1987).
33. Rosenstiel PE, Gruosso T, Letourneau AM et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int. 74(8), 1049-1058 (2008).
34. Pearce-Pratt R, Malamud D, Phillips DM. Role of the cytoskeleton in cell-to-cell transmission of human immunodeficiency virus. J. Virol. 68(5), 2898-2905 (1994). (Pubitemid 24129737)
35. Sylwester A, Wessels D, Anderson SA et al. HIV-induced syncytia of a T cell line form single giant pseudopods and are motile. J. Cell. Sci. 106, 941-953 (1993). (Pubitemid 23346807)
36. Levy DN, Fernandes LS, Williams WV, Weiner DB. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72(4), 541-550 (1993). (Pubitemid 23077742)
37. Fermin CD, Garry RF. Membrane alterations linked to early interactions of HIV with the cell surface. Virology 191(2), 941-946 (1992). (Pubitemid 23022498)
38. Groot F, van Capel TM, Schuitemaker J, Berkhout B, de Jong EC. Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 3, 1-10 (2006).
39. Hsia K, Spector SA. Human immunodeficiency virus DNA is present in a high percentage of CD4+ lymphocytes of seropositive individuals. J. Infect. Dis. 164, 470-475 (1991).
40. Ostrowski MA, Chun TW, Justement SJ et al. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J. Virol. 73, 6430-6435 (1999). (Pubitemid 29327821)
41. Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J. Virol. 79, 2199-2210 (2005). (Pubitemid 40204577)
42. Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur. J. Immunol. 34, 1705-1714 (2004). (Pubitemid 39256053)
43. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189, 1735-1746 (1999). (Pubitemid 29272690)
44. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signaling pathway to promote resting-cell infection. Nature 424, 213-219 (2003). (Pubitemid 36858691)
45. Kinter A, Moorthy A, Jackson R, Fauci AS. Productive HIV infection of resting CD4+ T cells: Role of lymphoid tissue microenvironment and effect of immunomodulating agents. AIDS Res. Hum. Retroviruses 19, 847-856 (2003). (Pubitemid 37338910)
46. Eckstein DA, Penn ML, Korin YD et al. HIV-1 actively replicates in naive CD4+ T cells residing within human lymphoid tissues. Immunity 15, 671-682 (2001). (Pubitemid 33016451)
47. Zhang Z, Schuler T, Zupancic M et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353-1357 (1999).
48. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: No easy answers. J. Virol. 77, 1659-1665 (2003). (Pubitemid 36109978)
49. Hermankova M, Siliciano JD, Zhou Y et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 77, 7383-7392 (2003). (Pubitemid 36734507)
50. Chun TW, Justement JS, Lempicki RA et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl Acad. Sci. USA 100, 1908-1913 (2003). (Pubitemid 36254547)
51. Zhu T, Muthui D, Holte S et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76, 707-716 (2002). (Pubitemid 34033369)
52. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999). (Pubitemid 29249429)
53. Lambotte O, Demoustier A, de Goër MG et al. Persistence of replication-competent HIV in both memory and naive CD4 T cell subsets in patients on prolonged and effective HAART. AIDS 16, 2151-2157 (2002). (Pubitemid 35387269)
54. Spina CA, Prince HE, Richman DD. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99, 1774-1785 (1997). (Pubitemid 27163830)
55. Woods TC, Roberts BD, Butera ST, Folks TM. Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 89, 1635-1641 (1997). (Pubitemid 27097457)
56. Robichaud GA, Barbeau B, Fortin JF, Rothstein DM, Tremblay MJ. Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+ T cells. J. Biol. Chem. 277, 23733-23741 (2002). (Pubitemid 34952214)
57. Ellery PJ, Tippett E, Chiu YL et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178, 6581-6589 (2007). (Pubitemid 46717442)
58. Le Douce V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 7, 1-16 (2010).
59. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49, 17-45 (2010).
60. Valentin A, Morrow M, Poirier RH et al. Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4+ primary cells. AIDS Res. Hum. Retroviruses 26, 79-88 (2010).
61. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antivir. Res. 82, 99-109 (2009).
62. Aquaro S, Svicher V, Schols D et al. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies. J. Leukoc. Biol. 80, 1103-1110 (2006). (Pubitemid 44646315)
63. Heeregrave EJ, Geels MJ, Baan E, van der Sluis RM, Paxton WA, Pollakis G. Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation. AIDS Res. Ther. 7, 1-8 (2010).
64. Turriziani O, Andreoni M, Antonelli G. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin. Microbiol. Infect. 16, 1518-1524 (2010).
65. Turriziani O, Boni A, Falasca F et al. Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patients. AIDS Res. Hum. Retroviruses 26, 625-634 (2010).
66. Delobel P, Sandres-Sauné K, Cazabat M et al. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS 19, 1739-1750 (2005). (Pubitemid 41546592)
67. Potter SJ, Lemey P, Achaz G et al. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. J. Leukoc. Biol. 76, 562-570 (2004). (Pubitemid 39129087)
68. Potter SJ, Dwyer DE, Saksena NK. Differential cellular distribution of HIV-1 drug resistance in vivo: Evidence for infection of CD8+ T cells during HAART. Virology 305, 339-352 (2003). (Pubitemid 36259668)
69. Fischer M, Joos B, Niederöst B et al. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5, 107 (2008).
70. Lane HC. Pathogenesis of HIV infection: Total CD4+ T-cell pool, immune activation, and inflammation. Top. HIV Med. 18, 2-6 (2010).